|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
We investigated the contribution of PAR4 to viral infections of the heart and lung.
|
31337508 |
2019 |
|
Vascular inflammations
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Protease-Activated Receptor PAR-4: An Inducible Switch between Thrombosis and Vascular Inflammation?
|
29044290 |
2017 |
|
Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The specific role of PAR-4 in thromboinflammatory vascular disease has been largely underestimated, given the relatively limited expression of PAR-4 in non-platelet cells under healthy conditions.
|
29044290 |
2017 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Proteinase-activated receptors (PARs) are a subfamily of G protein-coupled receptors (GPCRs) with four members, PAR1, PAR2, PAR3 and PAR4, playing critical functions in hemostasis, thrombosis, embryonic development, wound healing, inflammation and cancer progression.
|
24215724 |
2013 |
|
Tumor Progression
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
At this PIN transition, the mutual induction of Par-4 and PTEN is an additional regulatory step in preventing cancer progression.
|
19625770 |
2009 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
This indicates that the downregulation of Par-4 by oncogenic Ras is a critical event in tumor progression.
|
10562548 |
1999 |
|
Tumor Progression
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
That PAR4 expression difference in tumor progression possibly makes PAR4 become a molecular mark of tumor diagnosis.
|
25030438 |
2014 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The colorectal carcinoma cell LoVo showed an increased response to TFF2 as assessed by cell invasion upon PAR4 expression.
|
25876034 |
2015 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
We hypothesized that the platelet-induced epithelial sheet on PAR4-AP-modified titanium surfaces would reduce bacterial attachment, penetration, and invasion.
|
28086031 |
2017 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Induction of Par-4 (by NGD16 or ectopic overexpression) strongly impedes invasion with inhibition of major mesenchymal markers viz.
|
29672923 |
2018 |
|
Tumor Cell Invasion
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
Depletion of secretory Par-4 restored MMP-2 expression and invasion capability of HeLa and PC-3 cells.
|
22962598 |
2012 |
|
Thrombocytopenia due to platelet alloimmunization
|
0.010 |
Biomarker
|
disease |
BEFREE |
A reduction in response to GPVI and CLEC-2, but not protease-activated receptor 4 (PAR-4) peptide, was also observed in adult mouse platelets following immune thrombocytopenia, whereas receptor expression was not impaired.
|
29695020 |
2018 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Though PAR4 mRNA was detected in normal stomach, the role of PAR4 in gastric cancer has not been investigated.
|
21635966 |
2011 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Protease-activated receptor 4 (PAR4), a member of G-protein coupled receptors family, was recently reported to exhibit decreased expression in gastric cancer and esophageal squamous cancer, yet increased expression during the progression of prostate cancer.
|
25876034 |
2015 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our findings will be helpful in further investigations into the functions and molecular mechanisms of PAR4 in ESCC.
|
29502225 |
2019 |
|
Squamous cell carcinoma of esophagus
|
0.020 |
Biomarker
|
disease |
BEFREE |
Importantly, the chromatin immunoprecipitation-PCR (ChIP-PCR) data indicated that treatment of ESCC cells with PAR4-AP remarkably suppressed DNMT1 and HDAC2 enrichments on the p16 promoter.
|
30363984 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The decreased expression of protease-activated receptor 4 in esophageal squamous carcinoma.
|
25030438 |
2014 |
|
Septicemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thrombocytopenia, deficiency of PAR1 or PAR4 did not affect S. aureus sepsis survival, whereas hemophilia A increased mortality.
|
25690763 |
2015 |
|
Sepsis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Thrombocytopenia, deficiency of PAR1 or PAR4 did not affect S. aureus sepsis survival, whereas hemophilia A increased mortality.
|
25690763 |
2015 |
|
Secondary Neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
We hypothesized that thrombin, an activator of protease-activated receptor (PAR)-1 and PAR-4 contributes to tumor metastasis.
|
20857420 |
2011 |
|
Secondary malignant neoplasm of pancreas
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here, we conceive a dual mechanism of Par-4-mediated inhibition of EMT and induction of MET in metastatic pancreatic cancer cells.
|
29672923 |
2018 |
|
Secondary hypertension
|
0.010 |
PosttranslationalModification
|
disease |
BEFREE |
The aim of this work was to investigate the correlation between methylation of F2RL3 gene and coronary heart disease (CHD) with or without hypertension, secondary cardiovascular events and mortality.
|
30574762 |
2019 |
|
Renal Cell Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Specific lifestyle factors including tobacco-exposure are vital etiologic factors for renal cell carcinoma (RCC), F2R Like Thrombin/Trypsin Receptor 3 (F2RL3) is associated with smoking but it is unknown whether its expression translate into poor survival of clear cell RCC (ccRCC).
|
30271502 |
2018 |
|
Recurrent tumor
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
We previously reported that downregulation of the proapoptotic protein Par-4 promotes tumor recurrence in genetically engineered mouse models of breast cancer recurrence.
|
30148456 |
2018 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Stimulation of primary mouse ATII, MLE15 and A549 cells with thrombin (FIIa) - that may activate PAR-1, PAR-3 and PAR-4 - induced epithelial-mesenchymal transition (EMT), a process that has been suggested to be a possible mechanism underlying the expanded (myo)fibroblast pool in lung fibrosis.
|
23739922 |
2013 |